Abstract 2471 Anti-Cancer Activity of Acridine Derivatives in Cancer Cell Lines

Acridine compounds consist of a base structure similar to anthracene but with one of the central carbon-hydrogen groups replaced by Nitrogen and are being widely researched as potential cancer therapeutics. We have tested five different acridine derivatives on A549 (lung), PC3 (prostate), and BT5 (breast) cancer cell lines, all of which are a part of the NCI60 panel. An MTS assay, a colorimetric procedure, was used to measure cell viability at 48 hours after dosing with a final concentration of compound and compared to media and solvent controls.